Form 4 for INKT MiNK Therapeutics, Inc.
Accepted 2023-05-12 00:00:00 ET · period of report 2023-05-10 · accession 0000950170-23-021854 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-05-12 | 2023-05-10+ | INKT | AGENUS INC | 10% | P - Purchase | $1.47 | +45.4K | 21.62M | +0.2% | +$66.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-11 | P | A | 23,361 | $1.43 | 21,640,473 | D | — | — | (F3) Open market purchases reported on this line occurred at a weighted average price of $1.4275 (range of $1.38 to $1.495). (F2) Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. |
| 2 | Common | Common Stock | 2023-05-10 | P | A | 22,065 | $1.51 | 21,617,112 | D | — | — | (F1) Open market purchases reported on this line occurred at a weighted average price of $1.509 (range of $1.47 to $1.54). (F2) Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. |